Implications of population growth on prevalence of diabetes. A look at the future.

Diabetes Care

Health Policy Studies, American Enterprise Institute, Washington, DC 20036.

Published: March 1992

The purpose of this study was to present projections of the future population of diabetes patients, to discuss policy implications of these projections, and to suggest ways that these projections might be made more useful to medical professionals. Under the assumption that the incidence of diabetes in four age-groups will remain constant in future years, previous estimates of the incidence of diabetes will be applied to Bureau of the Census population projections to project the number of new cases of diabetes that can be expected in future years in each of these age-groups. The prevalence of diabetes will remain relatively constant at approximately 1 million patients in younger populations (less than 45 yr old) through the middle of the next century. As the post-World War II baby boom ages, the number of older diabetes patients (45 and older) will almost double from 6.5 million in 1987 to an estimated 11.6 million in the year 2030. Although there is little doubt that the aging of the population will increase the number of diabetes patients, the assumption of constant incidence rates is a very limiting one. These projections would be more useful for the planning of research and training if the incidence of diabetes could be estimated for more refined categories of demographic and medical characteristics.

Download full-text PDF

Source
http://dx.doi.org/10.2337/diacare.15.1.s6DOI Listing

Publication Analysis

Top Keywords

diabetes patients
12
incidence diabetes
12
diabetes
9
prevalence diabetes
8
will remain
8
remain constant
8
future years
8
diabetes will
8
projections
5
will
5

Similar Publications

Background: Adolescent diabetes is one of the major public health problems worldwide. This study aims to estimate the burden of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in adolescents from 1990 to 2021, and to predict diabetes prevalence through 2030.

Methods: We extracted epidemiologic data from the Global Burden of Disease (GBD) on T1DM and T2DM among adolescents aged 10-24 years in 204 countries and territories worldwide.

View Article and Find Full Text PDF

Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity.

Diabetol Metab Syndr

January 2025

Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People's Hospital of Nantong City, No.666 Shengli Road, Nantong, 226001, China.

Background: Increased glucagon levels are now recognized as a pathophysiological adaptation to counteract overnutrition in type 2 diabetes (T2D). This study aimed to elucidate the role of glucagon in peripheral nerve function in patients with T2D with different body mass indices (BMIs).

Methods: We consecutively enrolled 174 individuals with T2D and obesity (T2D/OB, BMI ≥ 28 kg/m), and 480 individuals with T2D and nonobesity (T2D/non-OB, BMI < 28 kg/m), all of whom underwent oral glucose tolerance tests to determine the area under the curve for glucagon (AUC).

View Article and Find Full Text PDF

Background: Anthracycline usage has been linked to cardiovascular adverse events (CAEs), which is unpredictable. It is critical to identify the characteristics of vulnerable populations and risk factors in order to reduce the occurrence of CAEs.

Objectives: This meta-analysis aimed to assess the correlation between various risk factors and CAEs induced by anthracyclines.

View Article and Find Full Text PDF

Background: Cytomegalovirus (CMV) can cause life-threatening diseases in immunosuppressed patients. Some of the patients with connective tissue disease develop CMV infection, and approximately half of this group has been reported to have received pulsed-methylprednisolone (p-MPSL) therapy. This study aimed to identify predictors of the onset of CMV infection in patients receiving p-MPSL therapy for connective tissue disease.

View Article and Find Full Text PDF

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis.

BMC Cardiovasc Disord

January 2025

The second Affiliated Hospital of Xi'an Jiaotong University, Xinjiang Hospital (People's Hospital of Xinjiang Uygur Autonomous Region, Bainiaohu Hospital), Urumqi, Xinjiang, 830026, People's Republic of China.

Background: Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!